Combined use of CDK4/6 and mTOR inhibitors induce synergistic growth arrest of diffuse intrinsic pontine glioma cells via mutual downregulation of mTORC1 activity

References

• FreemanCRFarmerJPPediatric brain stem gliomas: a reviewInt J Radiat Oncol Biol Phys19984022652719457808
   PubMed Web of Science ®Google Scholar
• SmithMAFreidlinBRiesLASimonRTrends in reported incidence of primary malignant brain tumors in children in the United StatesJ Natl Cancer Inst19989017126912779731733
   PubMedGoogle Scholar
• LongWYiYChenSCaoQZhaoWLiuQPotential new therapies for pediatric diffuse intrinsic pontine gliomaFront Pharmacol2017849528790919
   PubMed Web of Science ®Google Scholar
• HeilmannAMPereraRMEckerVCDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancersCancer Res201474143947395824986516
   PubMed Web of Science ®Google Scholar
• MalumbresMBarbacidMMammalian cyclin-dependent kinasesTrends Biochem Sci2005301163064116236519
   PubMed Web of Science ®Google Scholar
• Herrera-AbreuMTPalafoxMAsgharUEarly adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancerCancer Res20167682301231327020857
   PubMed Web of Science ®Google Scholar
• HidalgoMRowinskyEKThe rapamycin-sensitive signal transduction pathway as a target for cancer therapyOncogene200019566680668611426655
   PubMed Web of Science ®Google Scholar
• KwitkowskiVEProwellTMIbrahimAFDA approval summary: temsirolimus as treatment for advanced renal cell carcinomaOncologist201015442843520332142
   PubMed Web of Science ®Google Scholar
• MargolinKLongmateJBarattaTCCI-779 in metastatic melanoma: a phase II trial of the California Cancer ConsortiumCancer200510451045104816007689
   PubMed Web of Science ®Google Scholar
• GalanisEBucknerJCMaurerMJNorth Central Cancer Treatment GroupPhase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group StudyJ Clin Oncol200523235294530415998902
   PubMed Web of Science ®Google Scholar
• ZhaoHCuiKNieFThe effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer modelsBreast Cancer Res Treat2012131242543621394501
   PubMed Web of Science ®Google Scholar
• BecherOJGilheeneySWKhakooYA phase I study of perifosine with temsirolimus for recurrent pediatric solid tumorsPediatr Blood Cancer2017647
   PubMed Web of Science ®Google Scholar
• Killick-ColeCLSingletonWGBBienemannASRepurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine gliomaPLoS One2017125 e0176855
   PubMed Web of Science ®Google Scholar
• AsbyDJCudaFBeyaertMHoughtonFDCagampangFRTavas-soliAAMPK activation via modulation of de novo purine biosynthesis with an inhibitor of ATIC homodimerizationChem Biol201522783884826144885
   PubMedGoogle Scholar
• ArshadAYangBBienemannASConvection-enhanced delivery of carboplatin PLGA nanoparticles for the treatment of glioblastomaPLoS One2015107 e0132266
   Web of Science ®Google Scholar
• BartonKLMisuracaKCorderoFPD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem gliomaPLoS One2013810e7763924098593
   PubMed Web of Science ®Google Scholar
• Berenguer-DaizéCAstorgues-XerriLOdoreEOTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma modelsInt J Cancer201613992047205527388964
   PubMed Web of Science ®Google Scholar
• OlmezIBrennemanBXiaoACombined CDK4/6 and mTOR inhibition is synergistic against glioblastoma via multiple mechanismsClin Cancer Res201723226958696828814434
   PubMed Web of Science ®Google Scholar
• AokiYHashizumeROzawaTAn experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testingJ Neurooncol20121081293522231932
   PubMed Web of Science ®Google Scholar
• PiuntiAHashizumeRMorganMATherapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomasNat Med201723449350028263307
   PubMed Web of Science ®Google Scholar
• WeichhartTHengstschlägerMLinkeMRegulation of innate immune cell function by mTORNat Rev Immunol2015151059961426403194
   PubMed Web of Science ®Google Scholar
• AverousJFonsecaBDProudCGRegulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1Oncogene20082781106111317724476
   PubMed Web of Science ®Google Scholar
• Jhanwar-UniyalMGillickJLNeilJTobiasMThwingZEMuraliRDistinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexesAdv Biol Regul201557647425442674
   PubMedGoogle Scholar
• FrancoJWitkiewiczAKKnudsenESCDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerOncotarget20145156512652525156567
   PubMed Web of Science ®Google Scholar
• ChouTCTheoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studiesPharmacol Rev200658362168116968952
   PubMed Web of Science ®Google Scholar
• de GooijerMCZhangPThotaNP-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclibInvest New Drugs20153351012101926123925
   PubMed Web of Science ®Google Scholar
• HashizumeRAndorNIharaYPharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem gliomaNat Med201420121394139625401693
   PubMed Web of Science ®Google Scholar
• MonjeMMitraSSFreretMEHedgehog-responsive candidate cell of origin for diffuse intrinsic pontine gliomaProc Natl Acad Sci U S A2011108114453445821368213
   PubMed Web of Science ®Google Scholar
• MuellerSHashizumeRYangXTargeting Wee1 for the treatment of pediatric high-grade gliomasNeuro Oncol201416335236024305702
   PubMed Web of Science ®Google Scholar
• FrazierJLLeeJThomaleUWNoggleJCCohenKJJalloGITreatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategiesJ Neurosurg Pediatr20093425926919338403
   PubMed Web of Science ®Google Scholar
• JohungTBMonjeMDiffuse intrinsic pontine glioma: new pathophysiological insights and emerging therapeutic targetsCurr Neuropharmacol2017151889727157264
   PubMed Web of Science ®Google Scholar
• GrassoCSTangYTruffauxNFunctionally defined therapeutic targets in diffuse intrinsic pontine gliomaNat Med2015217827
   PubMed Web of Science ®Google Scholar
• LombardiGPambukuABelluLEffectiveness of antiangiogenic drugs in glioblastoma patients: a systematic review and meta-analysis of randomized clinical trialsCrit Rev Oncol Hematol20171119410228259301
   PubMed Web of Science ®Google Scholar
• Moreno-SmithMLakomaAChenZp53 nongenotoxic activation and mTORC1 inhibition lead to effective combination for neuroblastoma therapyClin Cancer Res201723216629663928821555
   PubMed Web of Science ®Google Scholar
• GeoergerBKieranMWGruppSPhase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcomaEur J Cancer201248225326222033322
   PubMed Web of Science ®Google Scholar
• City of Hope Medical CenterA feasibility, dose-escalation study using intracerebral microdialysis to assess the neuropharmacodynamics of temsirolimus in patients with primary or metastatic brain tumors Available from: http://www.clinicaltrials.gov/ct2/show/NCT00784914. NLM identifier: NCT00784914Accessed January 12, 2018
   Google Scholar
• PugetSPhilippeCBaxDAMesenchymal transition and PDG-FRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomasPLoS One201272e3031322389665
   PubMed Web of Science ®Google Scholar
• SchröderLBMcDonaldKLCDK4/6 inhibitor PD0332991 in glioblastoma treatment: does it have a uture?Front Oncol2015525926649278
   PubMed Web of Science ®Google Scholar
• PfizerA study of PD 0332991 in patients with recurrent Rb positive glioblastoma (PD0332991) Available from: https://www.clinicaltrials.gov/ct2/show/NCT01227434. NLM identifier: NCT01227434Accessed January 15, 2018
   Google Scholar
• Pediatric Brain Tumor ConsortiumPalbociclib isethionate in treating younger patients with recurrent, progressive, or refractory central nervous system tumors Available from: https://www.clinicaltrials.gov/ct2/show/NCT02255461. NLM identifier: NCT02255461Accessed January 16, 2018
   Google Scholar
• GoelSWangQWattACOvercoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitorsCancer Cell201629325526926977878
   PubMed Web of Science ®Google Scholar
• CorderoFJHuangZGrenierCHistone H3.3K27M represses p16 to accelerate gliomagenesis in a murine model of DIPGMol Cancer Res20171591243125428522693
   PubMed Web of Science ®Google Scholar
• SchreiberKHOrtizDAcademiaECAniesACLiaoCYKennedyBKRapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteinsAging Cell201514226527325652038
   PubMed Web of Science ®Google Scholar
• KhatuaSPetersonKMBrownKMOverexpression of the EGFR/FKBP12/HIF-2alpha pathway identified in childhood astrocytomas by angiogenesis gene profilingCancer Res20036381865187012702575
   PubMed Web of Science ®Google Scholar
• MinochaMKhuranaVQinBPalDMitraAKCo-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitorsInt J Pharm20124341–230631422633931
   PubMed Web of Science ®Google Scholar